NEOT:
I don't usually read or pay too much attention to comments on yahoo's threads <g>
As far as I can see:
"For the nine months ended 9/30/00, the Company reported no revenues. Net loss totaled $34.9 million, up from $13.8 million. Higher loss reflects costs associated with the conduct and expansion of clinical trials for the compound NEOTROFIN."
Insiders hold 51% and institutions 23% (47% of float). Book value reportedly is $1.02 with $1.00 cash/share and a current ratio of 3.18.
There are 13.3 M shares out with a float of 6.5 M, There reportedly are 1.28 M shares short (19.7% of float)with an average daily volume of 150,000 it seems about 8 1/2 days to cover, so there could be a potential "short squeeze".
This is some of today's news: (Remember that more than 50% of the time stocks that go up on news retrace a good part of the gain)<g>
LOS ANGELES, Jan 31 (Reuters) - NeoTherapeutics Inc. (NasdaqNM:NEOT - news) on Wednesday said a drug it is developing to treat Alzheimer's disease stimulated an increase in the number of brain stem cells in adult mice.
NeoTherapeutics said brain stem cells can restock the supply of mature neurons and may be the foundation of self-healing of the brain.
News of the studies on mice sent the shares of the Irvine, Calif.-based biopharmaceutical company up 1/2, or nearly 22 percent, to $2-13/16 in early trade on Nasdaq. The shares have a 52-week range of $2-3/16 to $27.
In two studies, mice received a single dose of the drug Neotrofin, and 24 hours later the number of newly formed brain stem cells in the mice was up significantly, NeoTherapeutics said.
The company is continuing to study whether the new cells will mature to become neurons, which initiate and conduct nerve impulses.
The company is developing Neotrofin, which induces production of natural protein molecules that regulate the growth and survival of neurons, as a potential treatment for neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
Neotrofin is already in clinical trials for treatment of Alzheimer's. In a Phase 2 study, patients treated with the drug experienced statistically significant improvement in memory, attention and judgment, the company said.
Bernard |
